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Cytomegalovirus (CMV) infection imposes a significant
economic burden on susceptible patients after renal
transplantation. Our study was conducted to determine the
prediction, probability, consequences, and treatment costs of
CMV infection under Canadian consensus guidelines in 270
sequential transplant patients. Transplant patients from
donors positive (Dþ ) for CMV into recipients negative (R)
for CMV received antiviral prophylaxis for 14 weeks and all
but donor negative (D)/R patients were monitored weekly
for the CMVpp65 marker expression. Marker-positive patients
and patients with CMV infection or disease received antiviral
treatment. Within the first 6 months, 27% of the 270 patients
tested had incidences of asymptomatic CMV infection, while
9% had CMV syndrome or disease. Only 1% of patients had
infection after 6 months. The CMVpp65 marker levels were
significantly greater in patients with syndrome or disease;
but post-test probabilities and predictive value of the marker
assay were low. Mean direct costs for care were $2256 and
ranged from $927 for D/R patients to $7069 in the Dþ /R
patients. Extension of antiviral prophylaxis to Dþ or Dþ /Rþ
patients significantly increased the estimated mean costs for
an absolute reduction to 4% in CMV syndrome or disease.
Our studies show that current guidelines for treatment
enable effective control of CMV infection; however,
alternative strategies have different economic impact.
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Cytomegalovirus (CMV) is the most important viral
pathogen following renal transplantation, and a leading
cause of infectious morbidity.1–3 CMV has also been
etiologically linked with acute rejection,4,5 chronic allograft
nephropathy,6 and reduced graft or patient survival, the latter
principally in CMV-negative recipients of CMV-positive
organs who did not receive antiviral prophylaxis.7–10 As a
consequence, CMV infection imposes a significant economic
burden due primarily to the increased frequency and cost of
hospitalization.9
The development of innovative antiviral agents has
substantially mitigated the clinical and economic impact of
this infection.11,12 Three principal strategies have been
advanced for the use of antiviral therapy: routine prophylaxis
during the first 3–4 months post-transplant,13 pre-emptive
antiviral therapy guided by laboratory monitoring of viral
expression,14–16 or deferred therapy instituted upon diagnosis
of clinical infection.17 Meta-analysis suggests that prophylaxis
is the most effective strategy,18,19 providing the greatest
reduction in disease incidence. Nonetheless, it is also the
most expensive and the optimal use of these approaches has
generated substantial debate.
The Canadian Consensus Guidelines on Cytomegalovirus
Management combines these strategies, employing routine
prophylaxis for high-risk CMV-seronegative recipients of
organs from a seropositive donor, with routine monitoring of
viral activation and administration of pre-emptive therapy in
other subjects.20 There are as yet no randomized comparisons
of this approach with other management strategies, so that
accurate modeling approaches assume importance in devel-
oping sound clinical and economic decision frameworks.
The application of evidence-based medicine requires an
objective understanding of the rates and consequences of key
events in clinical practice, which can be incorporated into
accurate models reflecting disease course and economic
impact.21 This analysis was therefore conducted to define the
principal parameters of CMV infection under conditions of
normal clinical practice in patients receiving standardized
anti-viral therapy according to the Canadian consensus
guidelines. The goal was to determine the following three
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critical factors: (a) the cumulative probability and principal
clinical outcomes of CMV antigenemia and CMV syndrome/
disease, (b) the prognostic value of CMV antigen monitoring
in predicting clinical infection under these circumstances,
and (c) the costs of antiviral therapy for prevention and
treatment of CMV infection, and the potential influence of
alternative treatment strategies on such costs.
RESULTS
Patients
Key patient characteristics are listed in Table 1. Of the 270
patients included in the study, 164 (62%) were male. Two
hundred and nineteen patients (81%) received a first graft
and 51 (18%) a second or subsequent graft. One hundred
and sixty-seven patients (62%) were CMV seropositive, and
151 (56%) received an organ from a seropositive donor. One
hundred and seventy (63%) received a live donor graft and
100 (37%) a cadaver graft. Eight patients (3%) received
induction therapy with depleting antibody, and 164 (60.7%)
with an anti-CD25 monoclonal antibody; 17 patients (6%)
commenced therapy with cyclosporine, 252 (94%) with
tacrolimus, and 268 (99%) received mycophenolate mofetil.
Seventeen patients received antithymocyte globulin (ATG) or
muromonab-CD3 (OKT3) for induction or treatment of
steroid-resistant acute rejection. The mean duration of
follow-up for the study was 1035 days (range 90–1980 days).
Probability of CMV infection
Kaplan–Meier estimates of CMV infection are shown in
Figure 1. A total of 96/270 patients (35%) developed CMV
infection, as determined by the presence of CMVpp65
antigen-positive cells in the peripheral blood, CMV syn-
drome, or CMV disease during the period of follow up.
Overall, 82% of cases (79/96) were diagnosed in the first 90
days (Q1), 14% (13/96) in Q2, 1% (1/96) in Q3, and 1% (1/96)
in Q4. CMV infection occurred almost exclusively within the
first 120 days in patients who did not receive antiviral
prophylaxis, thereafter reaching an asymptote. In contrast,
among patients who received prophylaxis, CMV infection
occurred from day 60, reaching a plateau at approximately
180 days. Only two patients developed CMV infection after
the first year, of whom one received prophylaxis and one did
not. Nine patients experienced recurrence of CMV infection a
mean of 1807112 days post-transplant and 87732 days after
diagnosis of first infection.
Only 23/270 (9%) patients developed CMV syndrome (21
patients, 8%) or tissue invasive disease (two patients, 1%) at
any time during observation. These occurred predominantly
within the first 6 months post-transplant (mean 68783
days), and four subjects (1.5%) experienced a second episode
a mean of 181730 days post-transplant. The case incidence
was greatest among patients in the Dþ /Rþ (15/118; 13%)
and Dþ /R (4/33; 12%) strata, the latter despite antiviral
prophylaxis; it was intermediate in frequency in D/Rþ
subjects (3/49; 6%) and least common in D/R recipients
(1/70; 1.5%) (Table 2). Three patients (1%) were hospitalized
for gastrointestinal complications of CMV infection for a
mean duration of 21.7 days (range 3–54 days), for a
hospitalization rate of 0.085 days per patient year at risk.
Predictive value of CMVpp65 antigenemia
Maximum CMVpp65 antigen expression ranged from 1 to
900 cells/2 105 polymorphonuclear cells (PMN) (median 7;
mean 28799/2 105 PMN). Forty-three patients (16%) had
a maximum of 1–3 cells, and 53 (20%) had a maximum of
X4 cells/2 105 PMN, the threshold employed for ther-
apeutic intervention. Maximum expression was higher in
those who developed CMV syndrome or disease (807187 vs
9712 cells/2 105 PMN) (P¼ 0001), but the highest levels
Table 1 | Demographic characteristics of study subjects according to occurrence of CMV infection
CMV infection No (n=174) Yes (n=96) Total (270) P-value
Recipient age (years) 45.4712.4 48.4713.3 46.4712.9 0.09
Donor age (years) 40.0712.4 40.4716.1 40.1713.8 0.75
Panel reactive antibody (%) 3.378.5 5.9714.4 4.1711.0 0.11
First graft (%) 138 (79%) 80 (83%) 218 (81%) 0.52
Living donor (%) 120 (69%) 50 (52%) 170 (63%) 0.008
Anti-CD25 antibody induction (%) 103 (59%) 61 (63%) 164 (61%) 0.51
Recipient CMV seropositive (%) 85 (49%) 82 (85%) 167 (62%) 1.08
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Figure 1 | Cumulative probability of CMV infection following
renal transplantation.
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frequently occurred during symptomatic infection hence
offering little predictive information.
The appearance of CMVpp65 antigenemia and subsequent
CMV syndrome or disease is shown in Figure 2. Eighty-three
patients developed CMVpp65 antigenemia of X1 cells/
2 105 PMN, including 6/33 (18%) who received antiviral
prophylaxis and 77/237 (32%) who did not. A total of 40 of
these had CMVpp65 antigen levels X4 cells/2 105 PMN
and received pre-emptive treatment, of whom 4 (10%)
subsequently progressed to CMV syndrome or disease. The
remaining 43 patients had CMVpp65 antigen levelso4 cells/
2 105 PMN and so did not receive pre-emptive treatment,
of whom six (14%) subsequently progressed to CMV
syndrome or disease (P¼ns). Of the remaining 187 subjects,
174 did not develop CMVpp65 antigenemia at any time
during the course of follow-up, whereas 13 (6%) developed
CMV pp65 antigenemia only during symptomatic infection.
CMVpp65 antigenemia showed poor performance in
predicting CMV syndrome or disease, whether examined as
a categorical or continuous variable. As shown in Table 3, for
patients with levels p3 CMVpp65-positive cells/2 105
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Figure 2 | Distribution of patients according to use of antiviral prophylaxis or pre-emptive therapy, and occurrence of asymptomatic or
symptomatic CMV infection.
Table 2 | Incidence of CMV infection stratified by risk group
Patient category Number CMVpp65 positive CMV syndrome CMV disease CMV pp65a (mean)
D+/R+ 118 50 (42%) 14 (12%) 1 (1%) 9720
DD+/R 33 5 (15%) 3 (9%) 1 (3%) 11715
D/R+ 49 14 (29%) 3 (6%) 0 (0%) 13726
D/R 70 4 (6%) 1 (1%) 0 (0%) 857270
Total 270 73 (27%) 21 (8%) 2 (1%) 29783
CMV, Cytomegalovirus; D, donors negative; D+, donors positive; R, recipients negative; R+, recipients positive.
aCMV pp65 antigenemia values=mean7s.d.
Table 3 | Performance of CMVpp65 antigen monitoring in predicting symptomatic CMV infection
Patients P Sensitivity Specificity LR(+) LR() PTP(+) PTP()
CMVpp65 antigen 1–3 cells/2 105 PMN—no pre-emptive treatment
Prophylaxisa — — — — — — —
No prophylaxis 0.08 0.38 0.81 1.98 0.77 0.15 0.06
Combined 0.08 0.31 0.82 1.80 0.83 0.14 0.07
CMVpp65 antigen X4 cells/2 105 PMN— received pre-emptive treatment
Prophylaxis 0.13 0.25 0.89 2.25 0.84 0.25 0.11
No prophylaxis 0.07 0.23 0.82 1.28 0.94 0.08 0.06
Combined 0.07 0.23 0.83 1.37 0.92 0.10 0.07
CMVpp65 antigen positive with or without pre-emptive treatment (both groups)
Prophylaxis 0.12 0.25 0.83 1.45 0.91 0.17 0.11
No prophylaxis 0.08 0.47 0.69 1.52 0.76 0.12 0.06
Combined 0.08 0.44 0.70 1.47 0.80 0.12 0.07
CMV, Cytomegalovirus; LR, likelihood ratio; PTP, post-test probability.
aNumbers of patients receiving prophylaxis who developed CMVpp65 antigenemia of 1–3 cells/2 105 PMN were too low to permit calculation of disease association.
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positive and negative likelihood ratios were 1.80 and 0.83, and
the positive and negative post-test probabilities were 0.14 and
0.07, respectively, little different from the pre-test probability
(prevalence) of 0.085 (23/270). It was impossible to establish
the independent prognostic value of CMVpp65 antigen levels
X4 cells/2 105 PMN, since such patients received pre-
emptive therapy. However, the sensitivity and specificity of
0.23 and 0.83, the positive and negative likelihood ratios of
1.37 and 0.92, and the positive and negative post-test
probabilities of 0.10 and 0.07, respectively, did not differ from
those of patients with lower antigenemia levels.
Antiviral therapy
The components of care and costs of antiviral therapy are
shown in Table 4. Patients in the Dþ /R stratum (n¼ 33)
received routine prophylaxis (mean 89 days, range 63–153
days). Patients in other serological strata (n¼ 17) who were
treated with ATG or OKT3 for induction therapy or
treatment of acute rejection received simultaneous short-
term antiviral prophylaxis (mean 7 days, range 3–10 days). A
total of 40 patients (15%) received pre-emptive antiviral
therapy (mean 37 days; range 7–61 days) and 22 patients
received treatment for symptomatic infection (mean 35 days;
Table 4 | Components of care and costs of antiviral management for CMV infection
D+/R+ D+/R D/R+ D/R All
Number of patients 118 33 49 70 270
1. Prophylaxis during first 14 weeks
Patients treated (number) 0 33 0 0 33
Duration (mean, days) — 89 — — 89
Cost per patient treated ($ Can) $0 $5206 $0 $0 $5206
Total cost of treatment ($ Can) $0 $171 798 $0 $0 $171 798
Mean cost per patient ($ Can) $0 $5206 $0 $0 $636
2. Prophylaxis during depleting antibody therapy
Patients treated (number) 12 0 5 0 17
Duration (mean, days) 7 — 7 — 7
Cost per patient treated ($ Can) $336 $0 $333 $0 $335
Total cost of treatment ($ Can) $4032 $0 $1665 $0 $5697
Mean cost per patient ($Can) $34 $0 $34 $0 $21
3. Pre-emptive therapy for CMVpp65 antigenemia
Patients treated (number) 30 4 6 0 40
Duration (mean, days) 36 28 48 0 37
Cost per patient treated ($ Can) $2433 $2929 $4023 $0 $2721
Total cost of treatment ($ Can) $72 990 $11 716 $24 138 $0 $108 844
Mean cost per patient ($Can) $619 $355 $493 $0 $403
4. Treatment of symptomatic infection
Patients treated (number) 14 4 3 1 22
Duration (mean, days) 43 28 44 35 38
Cost per patient treated ($ Can) $2939 $2122 $4847 $2809 $3045
Total cost of treatment ($ Can) $41 146 $8488 $14 541 $2809 $66 984
Mean cost per patient ($Can) $349 $257 $297 $40 $248
5. Monitoring of CMVpp65 antigenemia
Patients tested (number) 118 33 49 5 205
Assays performed (mean number) 18 20.3 16.8 3.4 14.6
Cost per patient monitored ($ Can) $778 $877 $726 $147 $631
Total cost of monitoring ($ Can) $91 757 $28 940 $35 562 $734 $156 993
Mean cost per patient ($ Can) $778 $877 $726 $11 $581
6. Costs of medical and nursing care
Episodes of care (number) 44 8 9 1 62
Costs per patient episode ($ Can) $289 $289 $289 $289 $289
Total costs of care ($ Can) $18 172 $3304 $3717 $413 $25 606
Mean cost per patient ($ Can) $154 $100 $76 $6 $96
7. Costs of hospitalization
Patients hospitalized (number) 0 1 1 1 3
Costs per patient hospitalized ($ Cad) $0 $9024 $3384 $60 912 $73 320
Mean costs per patient ($ Cad) $0 $273 $69 $870 $272
Total cost of therapy $228 097 $233 270 $83 007 $64 868 $609 242
Total cost per patient $1933 $7069 $1694 $927 $2256
CMV, Cytomegalovirus; LR, likelihood ratio; PTP, post-test probability.
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range 22–153 days), including four patients who experienced
recurrent CMV syndrome.
Treatment costs
Direct treatment costs for the base case are shown in Table 4.
The mean cost of prophylaxis for the Dþ /R cohort was
$5206 per treated patient, and of short-term prophylaxis for
patients who received ATG or OKT3 was $335 per treated
patient. The mean cost of pre-emptive therapy was $2721 per
treated patient, ranging from $0 in the D/R group to
$4023 in the D/Rþ group, whereas the mean cost of
treatment for CMV syndrome or disease was $3045, ranging
from $2122 in Dþ /R patients to $4847 in D/Rþ patients.
Total antiviral drug costs were greatest in the Dþ /R cohort
($5818), intermediate in the Dþ /Rþ ($1001) and D/Rþ
cohorts ($823), and lowest in the D/R cohort ($40). Mean
costs of CMV pp65 monitoring were $631, ranging from
$147 in the D/R cohort to $877 in the Dþ /R cohort,
whereas incremental medical/nursing costs were $413 per
episode of CMV infection and hospitalization costs ranged
from $0–$60 912 in the various risk strata. Total direct care
costs were $609 242, for a mean of $2256 per patient.
Scenario analysis
Three treatment scenarios were examined (Figure 3). Scenar-
io 1 recapitulated the base case in Table 4, but assumed for
maximum economic efficiency that CMV monitoring was
not required in subjects receiving full antiviral prophylaxis.
This reduced the total base case costs to $580 302, a saving of
$28 940.
Scenario 2 extended antiviral prophylaxis to all 151
patients with a CMV-positive donor. The number of Dþ /Rþ
patients requiring pre-emptive therapy was predicted to
decline from 30 (25%) to 10 (8%), and the number of those
requiring treatment for CMV syndrome/disease, from 14 (12%)
to 4 (3%), with a reduction in overall incidence of CMV
syndrome or disease from 22 (8%) to 12 patients (4%). Costs
of CMV monitoring declined to $36 297, medical/nursing
costs to $13 216, but hospitalization costs were unchanged
since no Dþ /Rþ patients were hospitalized. Total estimated
costs of care were $1 008 383, reflecting an increment of
$614 308 in prophylaxis and a reduction of $186 227 in
ancillary costs. Sensitivity analysis estimated total costs
ranging from $978 270 to $1 023 025 at the lower and upper
boundaries for pre-emptive therapy (0–10%) and treatment
(0–5%) respectively. Mean incremental cost-effectiveness
(cost per case of CMV syndrome/disease prevented) was
$42 808 (sensitivity range $28 426–54 324).
Scenario 3 employed universal prophylaxis in all 200
patients who were CMV donor or recipient positive. The
number of D/Rþ patients requiring pre-emptive therapy
was predicted to decline from 6 (12%) to 2 (4%), and the
number of those requiring treatment for CMV syndrome or
disease, from 3 (6%) to 0 (0%), for a reduction in overall
incidence of CMV syndrome or disease from 22 patients
(8%) to 9 patients (3%). Costs of CMV monitoring declined
to $734, medical/nursing costs to $10 325 and hospitalization
costs to $69 936. Total estimated costs of care were
$1 189 348, reflecting a further increment of $255 094 in
prophylaxis and a reduction of $74 127 in ancillary costs.
Sensitivity analysis estimated total costs ranging from
$1 180 486 to $1 204 308 at the lower and upper boundaries
for pre-emptive therapy (0–6%) and treatment (0–1%)
respectively. Mean incremental cost-effectiveness was
$46 850 (sensitivity range $46 166–$48 000).
DISCUSSION
Potent antiviral therapy has markedly reduced the incidence
and consequences of human CMV infection following renal
transplantation,22–28 but this therapy has important costs and
clinical consequences. Selection of optimal therapeutic
strategies to maximize clinical and cost-effectiveness has
been complicated by the heterogeneity of terminology and
treatment in this disorder,2,20,29,30 so that opinions and
practice are currently divided.13,14 Two principal therapeutic
approaches have been proposed: routine prophylaxis for 12
weeks or more from the time of transplantation in all patients
considered at high risk of infection,19,25,26,31,32 or pre-
emptive therapy, guided by evidence of viral proliferation
based on formal laboratory surveillance.16,17,33 Few direct
randomized comparisons have been conducted to enable
informed selection between these strategies in renal trans-
plantation,12,33–35 but meta-analysis suggests that universal
prophylaxis may be more effective, but likely more
expensive.18
The Canadian consensus strategy integrates these ap-
proaches, employing selective prophylaxis for Dþ /R
patients at greatest risk of clinical disease, while others are
monitored and treated only upon evidence of viral activation.20
Data reported here show that this approach enables effective
control of CMV infection following renal transplantation.
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Figure 3 | Estimated direct treatment costs for patient
populations according to antiviral prophylaxis strategy: scenario
1, prophylaxis for Dþ /R transplants only; scenario 2,
prophylaxis for all transplants with CMV-positive donor; scenario
3, prophylaxis for all transplants with a CMV-positive donor or
recipient.
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The case incidence of symptomatic infection of 8.5% is
consistent with current reports of treatment in patients at
high risk of infection,12 and contrasts markedly with the
incidence before 2000 when up to 70% of patients were
reported to develop symptomatic CMV infection.2,25,34,36,37
Despite the marked decline in cumulative probability, the
time-course of CMV infection was largely unchanged from
earlier periods.37 Over 90% of cases in this report occurred in
the first 6 months post-transplant, and late or recurrent
infection was uncommon. The hospitalization rate of 1% was
approximately half that reported in previous eras,38 but the
mean hospitalization time was not reduced emphasizing the
impact of this infection in the most serious cases.
Prophylaxis may be universal, administered to all
transplant recipients,39,40 or selective, administered only to
those at the highest risk of infection as defined by donor and
recipient serological status or use of depleting anti-lympho-
cyte antibodies.14,41 Both have been shown to be effective in
reducing the case incidence of infection. Selective prophylaxis
employed in this study population resulted in a case
incidence of infection in Dþ /R recipients comparable to
that in Dþ /Rþ recipients, so that the overall prevalence
remained substantially higher in recipients of an organ from
a CMV-positive donor.37,42 The current analysis was not
designed to permit rigorous comparison between the
antiviral agents employed, and though a small, statistically
non-significant decline observed in the incidence of CMV
infection following the introduction of valganciclovir may
reflect the demonstrated efficacy and superior bioavailability
of this agent,28 no clear relationship was observed between
the antiviral drugs or dosages employed and the occurrence
or severity of infection or the risk of drug resistance.13,14,43
However, since the majority of infections in patients receiving
prophylaxis occurred following completion of therapy,41,44
prolongation of prophylaxis may be a legitimate considera-
tion.22,40,41,45
Pre-emptive therapy, in contrast, is targeted to selected
patients on detection of viral activation,15–17,33,35 facilitating
normal immune priming and development of appropriate
CMV-specific T-cell and B-cell immunity while minimizing
drug toxicity, treatment cost, and risks of drug resistance.14
Meta-analysis indicates that pre-emptive therapy is signifi-
cantly more effective than placebo or standard care in
reducing the risk of CMV disease in recipients of kidneys
from a CMV-seropositive donor (relative risk 0.29,
P¼ 0.02),16 but may be slightly less effective than prophylaxis
(odds ratio 0.28 vs 0.20), particularly in Dþ /R recipients at
the highest risk (odds ratio: 0.36 vs 0.20).18 Effective pre-
emption requires precise detection of virus activation and
reliable prediction of disease risk, however. Assays used for
this purpose, including the measurement of CMV-specific
IgG and IgM antibodies, quantitation of viral load, detection
of the CMVpp65 antigen expression, and direct viral
culture,46–49 vary importantly in their sensitivity, specificity,
and predictive value within the clinical setting, and few have
been subjected to rigorous multicenter study to validate their
clinical utility.20,46 These limitations are illustrated with the
measurement of CMVpp65 antigenemia in this report, in
which the threshold for pre-emptive therapy was established
at the lower boundary of the proposed range to maximize
sensitivity.50–52 While maximum expression was significantly
higher in patients who developed symptomatic infection, the
highest levels frequently occurred during the symptomatic
episode, hence offering little predictive information and
CMVpp65 antigenemia showed poor performance in pre-
dicting symptomatic CMV infection whether examined as a
categorical or continuous variable.
Management of CMV infection has an important
economic impact in transplantation. We have previously
shown that mean total institutional costs were 2.5 times
greater for patients with CMV disease than for matched
controls, reflecting primarily an increase in ward, hotel,
laboratory, and pharmacy costs.9 More recent data have
confirmed the importance of this infection as a critical cost-
driver and risk for hospitalization,38,53 and have emphasized
the cumulative indirect costs of co-infection and graft loss.7
Modern antiviral therapy has substantially mitigated this
economic burden, but treatment remains expensive and
optimization of therapy is therefore important.34 An
important objective of this study was to examine the direct
therapeutic costs of the consensus guidelines for management
of CMV infection under condition of normal clinical
practice. The data reported here show that the use of the
current consensus guidelines imposes a mean incremental
cost of $2256 per patient, ranging from $927 per patient in
the D/R stratum to $7069 per patient in the Dþ /R
stratum. Use of routine prophylaxis in all recipients of grafts
from a CMV-seropositive donor increases the mean cost to
$4405 per patient, representing an incremental cost of
$46 850 per case of symptomatic infection prevented. While
prophylaxis for patients in the Dþ /Rþ and D/Rþ strata
reduced the mean costs of CMVpp65 monitoring, medical
and nursing care, and hospitalization, the incremental costs
of antiviral drug costs remained a dominant influence.54
In summary, current antiviral therapy is highly effective in
managing CMV infection following renal transplantation,
and the incidence and consequences of clinical infection
appear to be substantially less than reported in previous eras.
Prophylaxis is valuable in patients at highest risk of clinical
infection, but costs must be balanced against the more
limited reduction in case rate for patients at lower risk. While
pre-emptive therapy is attractive to minimize toxicity and
costs, the predictive value of current monitoring tools is low
and detracts from the specificity of this approach. Combined
strategies such as that reported here appear to be a reasonable
interim solution pending more specific measures of predict-
ing and preventing infection with delayed therapy.
This is particularly true in a period when rapid advances
in immunological understanding and intervention are
driving important improvements in clinical outcomes.55–57
We have previously presented comprehensive decision-
analytic models of renal transplantation that encompass
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principal clinical interventions, outcomes, and costs of
therapy and permit the comparison of diagnostic or
treatment parameters, enabling the hypothesis-generated
comparison of biomarker use and management options.58,59
Such models require detailed, accurate, and current para-
meterization for key variables.
MATERIALS AND METHODS
Study design
This stratified cohort study examined all consecutive patients
receiving a renal transplant from January 1, 2000 to December 31,
2004 at a single university center. The patient sample and period of
observation were selected to ensure standard medical practice and
immunosuppressive therapy, and the application of Canadian
consensus clinical guidelines for the prevention, diagnosis and
treatment of CMV infection.20 All patients were followed prospec-
tively by the transplant program, with no loss to follow-up during
the period of study. All data were recorded prospectively in the
electronic program database, and all charts were reviewed retro-
spectively to ensure concordance with the archived data.
Renal transplantation
All transplant recipients had a negative anti-human globulin
complement-dependent cytotoxicity T-cell cross-match. Routine
immunosuppression consisted of treatment with a non-depleting
anti-CD25 antibody (basiliximab, 20 mg on days 0 and 4), with
cyclosporine 10 mg/kg/day or tacrolimus 0.075 mg/kg/bid, myco-
phenolate mofetil 2000 mg/day, and prednisone commencing at
125 mg intravenous (i.v.) on the day of transplantation and
declining to 7.5 mg/day on alternate days or withdrawal in low-
risk first-graft recipients. Patients with a Panel Reactive Antibody
titer 460%, who had previously been transplanted received
induction therapy with ATG (Thymoglobulin, SangStat Medical
Corporation, Fremont, CA, USA) or OKT3. Acute graft rejection
was diagnosed by clinical and laboratory findings and confirmed by
biopsy. Rejection episodes were treated with solumedrol 500 mg i.v.
for 3–5 days, and steroid-resistant rejections with OKT3 or ATG
daily for 7–10 days.
CMV infection
Living donor recipients were transplanted independent of donor
and recipient CMV serostatus, whereas cadaver organs were
allocated preferentially to CMV-matched patients. Peripheral blood
from all but D/R (donor CMV seronegative/recipient CMV
seronegative) patients was obtained weekly during the first 4 months
post-transplant, and was tested for CMVpp65 antigenemia within
6 h of blood collection using the CMVpp65 immunofluorescence
assay (DiaSorin Inc., Stillwater, MN, USA). CMV infection was
defined according to the Canadian Society of Transplantation
consensus on CMV management in solid organ transplantation.20
Asymptomatic CMV infection was defined by detection of
CMVpp65 antigen in more that one cell per 2 105 PMN, or
detection of CMV DNA by PCR in one blood sample in the absence
of concurrent symptoms of viral infection. CMV syndrome was
defined by the presence of fever above 381C, with at least one of the
following: malaise, leucopenia, X5% atypical lymphocytes, throm-
bocytopenia, elevation of alanine aminotransferase (ALT) or
aspartate aminotransferase (AST), along with evidence of CMV in
blood by viral culture, antigenemia, or a DNA/RNA-based assay, in
the absence of another identified cause of symptoms. Tissue invasive
CMV disease was defined by the presence of CMV symptoms and
the detection of CMV in tissue by immunohistochemical analysis or
in situ hybridization.
CMV therapy
Prophylactic antiviral therapy. This was administered only to
CMV-mismatched Dþ /R transplant recipients. These patients
received ganciclovir 5 mg/kg i.v. twice daily (b.i.d.) until discharge
(mean 6 days), followed by oral ganciclovir 3000 mg p.o. daily before
2003 or valgancyclovir 900 mg p.o. daily thereafter for an additional
12–14 weeks, adjusted according to graft function. CMV-seroposi-
tive recipients treated with ATG or OKT3 for induction or treatment
of acute rejection also received antiviral prophylaxis, typically
ganciclovir 5 mg/kg i.v. b.i.d. adjusted for renal function during the
period of antibody therapy (range 4–10 days).
Pre-emptive antiviral therapy. This was administered to all
patients who developed CMVpp65 antigenemiaX4 cells per 2 105
PMN. Before 2003, pre-emptive therapy consisted of oral ganciclovir
3000 mg/day; beyond that date patients received intravenous
ganciclovir 5/mg/kg b.i.d. for 2 weeks, adjusted for renal function,
followed by valgancyclovir 900 mg p.o. daily, until the CMVpp65
antigenemia was negative for two successive weeks. CMVpp65
antigenemia was tested for a further 8 weeks to detect recrudescence.
Patients with recurrent antigenemia received valgancyclovir 900 mg
per day until the CMVpp65 antigenemia was negative for 2
successive weeks.
Antiviral treatment. Patients who developed symptomatic
CMV infection received ganciclovir 5 mg/kg i.v. b.i.d. for two weeks,
followed by 5 mg/kg i.v. daily 5 days per week for an additional 4
weeks, then valgancyclovir 900 mg daily until CMVpp65 antigene-
mia was negative for two consecutive weeks and the patient was
clinically stable. CMV antigenemia testing was continued for the
next 12 weeks.
Cost analysis
A decision model was constructed to evaluate the direct costs of
antiviral therapy for patients receiving a de novo kidney transplant.
The perspective was that of a health provider within the Canadian
health care system and the primary time horizon was 12 months.
Probabilities were derived from the observed values for infection
and treatment, reported in Table 2 and Figure 2, and ranges for
scenario analysis from the literature and expert consensus. The cost
vector was obtained by detailed review and aggregated into seven
components: routine prophylaxis, prophylaxis for depleting anti-
body therapy, pre-emptive therapy, treatment of symptomatic
infection, monitoring of CMVpp65 antigenemia, incremental
physician and nursing care, and hospitalization.
CMV pp65 monitoring costs of $43.20 per assay included sample
acquisition, processing, and technical and professional components.
Physician and nursing time was valued at $125/hour and $40/hour,
respectively. Review of negative results did not require incremental
time, but a mean of 2.5 h of physician and nurse time was allocated
for each episode of CMV antigenemia, syndrome, or disease
requiring treatment.12 Drug acquisition costs were provided by the
hospital pharmacy, and comprised intravenous ganciclovir, $41.22
per 500 mg vial; oral ganciclovir $9.00 per 500 mg capsule;
valganciclovir, $22.41 per 450 mg tablet; and foscarnet, $94.20 per
6000 mg vial (estimated as $65.94 per day). Costs for intravenous
therapy in hospital were included in the normal costs of
hospitalization. Incremental costs for intravenous therapy at home
were provided by the regional Home Intravenous Therapy Program
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and comprised nursing costs of $64.29 per day during first 14 days,
and $34.29 per day thereafter, and ancillary supplies, containers, i.v.
pole rental, pick up, deliveries, etc. estimated at $360.00 per
treatment course/patient. Costs of hospitalization were documented
for each admission.
Data analysis
The times to CMV infection, acute rejection, and graft loss or death
were analyzed using survival analysis methods. Patients not
experiencing these events during the post-transplant observation
period were censored at the latest point of follow-up. The log-rank
test was used to compare Kaplan–Meier estimates of CMV infection
and other outcomes in patients with or without CMVpp65
antigenemia or symptomatic CMV infection, with and without
stratification for key demographic and treatment variables. Sensi-
tivity, specificity, likelihood ratios, and positive (PTPþ ) and
negative post-test probabilities (PTP) were calculated to measure
the predictive value of CMV antigenemia for subsequent clinical
infection.60,61
ACKNOWLEDGMENTS
We are indebted to the members of the Genome Canada Biomarkers
in Transplantation Group: Dr David Landsberg, Dr John Gill, Dr Bruce
McManus, Dr Rob McMaster, Dr Paula Kebarle, Dr Nilu Partovi, and to
the members of the Health Economics Departments in Novartis
Pharma and Roche Pharma for their contribution to and critical
review of this paper. This research was supported in part by a grant-
in-aid from Novartis Pharma, Basle in conjunction with the Genome
Canada award for Biomarkers in Transplantation. None of the authors
have any conflict of interest in the research reported in this article.
REFERENCES
1. Keay S. CMV infection and disease in kidney and pancreas transplant
recipients. Transpl Infect Dis 1991; 1(Suppl 1): 19–24.
2. Brennan D. Cytomegalovirus in renal transplantation. J Am Soc Nephrol
2001; 12: 848–855.
3. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus
infection and disease on rejection episodes in renal allograft recipients.
Am J Transplant 2002; 2: 850–856.
4. Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-
related disease and risk of acute rejection in renal transplant recipients: a
cohort study with case–control analyses. Transplant Int 2000; 13: 413–419.
5. Reischig T, Jindra P, Svecova M et al. The impact of cytomegalovirus
disease and asymptomatic infection on acute renal allograft rejection.
J Clin Virol 2006; 36: 146–151.
6. Tong C, Bakran A, Peiris J et al. The association of viral infection and
chronic allograft nephropathy with graft dysfunction after renal
transplantation. Transplantation 2002; 74: 576–578.
7. Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J
Health Syst Pharm 2003; 60: S5–S8.
8. Nett P, Heisey D, Fernandez L et al. Association of cytomegalovirus
disease and acute rejection with graft loss in kidney transplantation.
Transplantation 2004; 78: 1036–1041.
9. McCarthy J, Karim M, Krueger H et al. The cost impact of cytomegalovirus
disease in renal transplant recipients. Transplantation 1993; 55:
1277–1282.
10. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft
outcome in solid organ transplantation: a collaborative transplant study
report. Am J Transplant 2004; 4: 928–936.
11. Drummer S. Controlling the Troll: management of cytomegalovirus
infection after transplantation. Ann Int Med 2005; 143: 913–914.
12. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral
valganciclovir for the management of cytomegalovirus infection in adult
renal transplant recipients. Am J Transplant 2006; 6: 2134–2143.
13. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive
therapy in solid organ transplantation. Rev Med Virol 2001; 11:
73–81.
14. Emery V. Prophylaxis for CMV should not now replace pre-emptive
therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83–86.
15. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65
antigen-guided preemptive therapy with ganciclovir in solid organ
transplant recipients: a prospective, double-blind, placebo-controlled
study. Transplantation 2001; 72: 1325–1327.
16. Strippoli GFM, Hodson EM, Jones C et al. Pre-emptive treatment for
cytomegalovirus viremia to prevent cytomegalovirus disease in solid
organ transplant recipients. Transplantation 2006; 81: 139–145.
17. Brennan DC, Garlock KA, Lippmann BA et al. Control of cytomegalovirus-
associated morbidity in renal transplant patients using intensive
monitoring and either preemptive or deferred therapy. J Am Soc Nephrol
1997; 8: 118–125.
18. Kalil A, Levitsky J, Lyden E et al. Meta-analysis: the efficacy of strategies to
prevent organ disease by cytomegalovirus in solid organ transplant
recipients. Ann Int Med 2005; 143: 870–880.
19. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirus prophylaxis
with antiviral agents in solid organ transplantation: a meta-analysis.
Transplantation 1998; 65: 641–647.
20. Preiksaitis J, Brennan D, Fishman J et al. Canadian society of
transplantation consensus workshop on cytomegalovirus management
in solid organ transplantation final report. Am J Transplant 2005; 5:
218–227.
21. Akobeng A. Principles of evidence based medicine. Arch Dis Child 2005;
90: 837–840.
22. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the
prevention of cytomegalovirus disease after renal transplantation. N Engl
J Med 1999; 340: 1462–1470.
23. Balfour H, Chace B, Stapleton J et al. A randomized, placebo-contolled
trial of oral acyclovir for the prevention of cytomegalovirus disease in
recipients of renal allografts. N Engl J Med 1989; 320: 1381–1387.
24. Verheyden JP. Evolution of therapy for cytomegalovirus infection. Rev Inf
Dis 1988; 10(Suppl 3): S477–S489.
25. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T et al. Long-term oral
ganciclovir prophylaxis for prevention of cytomegalovirus infection and
disease in cytomegalovirus high-risk renal transplant recipients.
Transplantation 2000; 70: 1174–1180.
26. Lake K. New prophylactic treatment strategy for cytomegalovirus disease.
Am J Health Syst Pharm 2003; 60: S13–S16.
27. Kletzmayr J, Kotzmann H, Popow-Kraupp T et al. Impact of high-dose oral
acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk
renal transplant recipients. J Am Soc Nephrol 1996; 7: 325–330.
28. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir
vs oral ganciclovir for prevention of cytomegalovirus disease in solid
organ transplant recipients. Am J Transplant 2004; 4: 611–620.
29. Ketteler M, Kunter U, Floege J. An update on herpes virus infections in
graft recipients. Nephrol Dial Transplant 2003; 18: 1703–1706.
30. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus
infection and disease in transplant recipients. Clin Infect Dis 2002; 34:
1094–1097.
31. Taber D, Ashcraft E, Baillie G et al. Valganciclovir prophylaxis in patients at
high risk for the development of cytomegalovirus disease. Transpl Infect
Dis 2004; 6: 101–109.
32. Uknis ME. Prophylaxis of cytomegalovirus disease in transplant patients.
Am J Health Syst Pharm 2005; 62: S3–S6.
33. Sagedal S, Nordal KP, Hartmann A et al. Pre-emptive therapy of CMVpp65
antigen positive renal transplant recipients with oral ganciclovir: a
randomized, comparative study. Nephrol Dial Transplant 2003; 18:
1899–1908.
34. Brennan D, Garlock K, Singer G et al. Prophylactic oral ganciclovir
compared with deferred therapy for control of cytomegalovirus in renal
transplant recipients. Transplantation 1997; 64: 1843–1846.
35. Hibberd P, Snydman D. Cytomegalovirus infection in organ transplant
recipients. Inf Dis Clin North Am 1995; 9: 863–877.
36. Rubin R. Infection in the organ transplant recipient. In: Rubin R, Young L
(eds). Clinical Approach to Infection in the Compromised Host, 3rd edn,
Plenum Press: New York, 1994, pp 629–705.
37. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural
course of cytomegalovirus infection and disease in renal allograft
recipients. Transplantation 2000; 70: 1166–1174.
38. Abbott K, Hypolite I, Viola R et al. Hospitalizations for cytomegalovirus
disease after renal transplantation in the United States. Ann Epidemiol
2002; 12: 402–409.
39. Wright Jr FH, Banowsky LH. Cytomegalovirus infection and prophylaxis in
renal transplantation: financial considerations. Transplant Proc 1998; 30:
1318–1319.
40. Gabardi S, Magee C, Baroletti S et al. Efficacy and safety of low-dose
valganciclovir for prevention of cytomegalovirus disease in renal
Kidney International (2007) 72, 1014–1022 1021
S Dmitrienko et al.: Managing CMV infection in renal transplantation o r i g i n a l a r t i c l e
transplant recipients: a single-center, retrospective analysis.
Pharmacotherapy 2004; 24: 1323–1330.
41. Murray B, Subramaniam S. Late cytomegalovirus infection after oral
ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis
2004; 6: 3–9.
42. McLaughlin K, Sandhu S, Muirhead N et al. Transplanting kidneys from
CMV-seropositive donors to CMV-seronegative recipients is not
associated with poorer renal allograft function or survival. Nephrol
Dialysis Transplant 2005; 20: 176–180.
43. Humar A, Kumar D, Boivin G et al. Cytomegalovirus (CMV) virus load
kinetics to predict recurrent disease in solid-organ transplant patients
with CMV disease. J Inf Dis 2002; 186: 829.
44. Singh N. Delayed occurrence of cytomegalovirus disease in organ
transplant recipients receiving antiviral prophylaxis: are we winning the
battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002; 21: 902.
45. Doyle A, Warburton K, Goral S et al. 24-Week oral ganciclovir prophylaxis
in kidney recipients is associated with reduced symptomatic
cytomegalovirus disease compared to a 12-week course. Transplantation
2006; 81: 1106–1111.
46. Tong C, Cuevas L, Williams H et al. Use of laboratory assays to predict
cytomegalovirus disease in renal transplant recipients. J Clin Microbiol
1998; 36: 2681–2685.
47. Tong C, Cuevas L, Williams H et al. Prediction and diagnosis of
cytomegalovirus disease in renal transplant recipients using qualitative
and quantitative polymerase chain reaction. Transplantation 2000; 69:
985–991.
48. Kim C, Song J-H, Kim S-M et al. Clinical usefulness of human
cytomegalovirus antigenemia assay after kidney transplantation.
Transplantation 2003; 75: 2151–2155.
49. Hassan-Walker I, Kidd I, Sabin C et al. Quantity of human cytomegalovirus
(CMV) DNAemia as a risk factor for CMV disease in renal allograft
recipients: Relationship with donor/recipient CMV serostatus, receipt of
augmented methylprednisolone and antithymocyte globulin (ATG).
J Med Virol 1999; 58: 182–187.
50. Meyer-Koenig U, Weidmann M, Kirste G et al. Cytomegalovirus infection
in organ-transplant recipients: diagnostic value of pp65 antigen test,
qualitative polymerase chain reaction (PCR) and quantitative Taqman
PCR. Transplantation 2004; 77: 1692–1698.
51. Bernabeu-Wittel M, Pachon-Ibanez J, Cisneros J et al. Quantitative pp65
antigenemia in the diagnosis of cytomegalovirus disease: prospective
assessment in a cohort of solid organ transplant recipients. J Infect 2005;
51: 188–194.
52. Schroeder R, Michelon T, Fagundes I et al. Antigenemia for
cytomegalovirus in renal transplantation: choosing a cutoff for the
diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005; 37:
2781–2783.
53. Hagenmeyer EG, Haussler B, Hempel E et al. Resource use and treatment
costs after kidney transplantation: impact of demographic factors,
comorbidities, and complications. Transplantation 2004; 77: 1545–1550.
54. Tilden D, Chapman J, Davey P et al. A decision-analytic economic
evaluation of valaciclovir prophylaxis for the prevention of
cytomegalovirus infection and disease in renal transplantation. Clin
Transplant 2004; 18: 312–320.
55. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol
Hypertens 1998; 7: 659–663.
56. Buhaescu I, Segall L, Goldsmith D et al. New immunosuppressive
therapies in renal transplantation: monoclonal antibodies. J Nephrol 2005;
18: 529–536.
57. Woodroffe R, Yao G, Meads C et al. Clinical and cost-effectiveness of
newer immunosuppressive regimens in renal transplantation: a
systematic review and modelling study. Health Technol Assess 2005; 9:
1–194.
58. Keown PA, Kiberd B, Balshaw R et al. An economic model of two-hour
post-dose cyclosporine monitoring in renal transplantation.
Pharmacoeconomics 2004; 22: 621–632.
59. Keown PA, Balshaw R, Krueger H et al. An economic model of Simulect in
renal transplantation. Transplantation 2001; 71: 1573–1579.
60. Schechter MT, Sheps SB. Diagnostic testing revisited: pathways through
uncertainty. CMAJ 1985; 132: 755.
61. LaBaer J. So, you want to look for biomarkers. J Proteome Res 2005; 4:
1053–1059.
1022 Kidney International (2007) 72, 1014–1022
o r i g i n a l a r t i c l e S Dmitrienko et al.: Managing CMV infection in renal transplantation
